When the X-rays flash on screen at Keeneland, a hush sometimes falls over the bidders’ circle—there, in the delicate bones of a yearling’s knee, a tiny shadow: a carpal chip. For decades, that shadow has spelled risk. Buyers have stepped back. Prices have tumbled. But now, research from the University of Kentucky’s Maxwell H. Gluck Equine Research Center is turning that long-held belief on its head. In a groundbreaking study, Thoroughbred yearlings with surgically removed knee chips didn’t just compete—they thrived, matching their so-called ‘clean’ counterparts in both sales performance and racing success. This isn’t just veterinary insight; it’s a potential game-changer for an industry where perception often trumps reality.
Led by Dr. Bruno Menarim and drawing on clinical records from Hagyard Equine Medical Institute between 2015 and 2018, the study followed 46 Thoroughbred yearlings with carpal osteochondral fragments—commonly known as knee chips. Twenty-six underwent arthroscopic surgery before going to auction; 20 were managed without surgery. To ensure fairness in comparison, researchers matched them with 138 siblings of the same sire and sale year who showed no radiographic abnormalities. Then, they waited. By June 2023, nearly every horse had completed its racing career, offering a rare, full-picture analysis of long-term outcomes.
The results were striking. Yearlings who had surgery sold for roughly the same price as their chip-free peers—no statistically significant difference. Their total career earnings? Also on par. They started just as often, raced just as long, and reached the same class of races. But the untreated group told a different story. Those with chips left in place were heavily discounted at auction and earned significantly less over their careers. The financial penalty was clear: untreated horses faced a steep disadvantage. Even more telling, the average sale price difference between surgically treated and untreated yearlings was nearly $2,000—just over the cost of the surgery itself. In essence, the procedure paid for itself.
"That difference is almost the cost of removing the fragment," Menarim said. "So go ahead and do the surgery, and you're increasing the likelihood that this horse is going to have sales appeal—and a better chance of a meaningful racing career." The surgery doesn’t just preserve joint health; it preserves opportunity. And in a sport where a single race can define a legacy, that’s everything.
This study doesn’t erase risk, but it reframes it. With modern arthroscopic techniques, a once-dreaded diagnosis no longer needs to be a career limiter. For breeders, sellers, and young horses with bright futures, that’s not just hopeful—it’s transformative.